Hadasit Bio-Holdings


Investing in Hadassah Based Biotech Companies

Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for the majority of Israel's hospital-based translational research.

The HBL traded stock, as a unique investment vehicle, provides investment exposure to a select portfolio of 6 biotech companies - all based on inventions developed and owned by Hadassah. The companies operate in the fields of Oncology (Rx and Dx), Regenerative Medicine and Inflammatory Disease.

HBL focuses on funding the preparation for and execution of Phase I and preparation for Phase II by the portfolio companies. Preparations include pre-clinical trials, manufacturing, regulatory and business development tasks.

HBL utilizes a competitive advantage symbolized as triple “ I " : I nnovation, I nfrastructure & I nvestment.

youtube icon linkedin icon twitter icon facebook,social,social network,sn

Latest News

Nov. 19, 2018
הודעה לבעלי המניות בחברה על כינוס אסיפה כללית מיוחדת

Jun. 28, 2018
אייץ' בי אל- הדסית ביו-החזקות בע"מ ("החברה") הודעה לבעלי המניות בחברה על כינוס אסיפה כללית שנתית ומיוחדת

Sep. 1, 2016
הודעה על פרסום דוח הצעת מדף

Jun. 30, 2016
הודעה על כינוס אסיפה כללית מיוחדת של בעלי המניות של החברה

Jun. 21, 2016
Notification of the termination of ADS listing and trading

Jun. 8, 2016
Written Vote under the Companies Regulations

May. 30, 2016
הודעה על כינוס אסיפה כללית שנתית מיוחדת של בעלי המניות של החברה

Feb. 21, 2016
Written Vote under the Companies Regulations

Feb. 17, 2016
investment transaction in the Kahr Medical (2005) Company Ltd.

Feb. 14, 2016
Investment in Cell Cure Neurosciences Ltd.

Feb. 9, 2016
Investment in Cell Cure Neurosciences Ltd.

Feb. 3, 2016
Receipt of Helsinki Approval for Phase I/IIa Clinical Trial at Tel Hashomer by KAHR Medical Ltd. (“KAHR”)

Jan. 3, 2016
Investment in Kahr Medical

Dec. 20, 2015
Results of a Public Offering According to its Shelf Offer Report from December 16, 2015

Dec. 15, 2015
Investment Transaction in KAHR Medical (2005) Ltd.

Dec. 1, 2015
Helsinki Approval for Stage I/IIa Clinical Trials of KAHR Medical Ltd.

Nov. 18, 2015
Convertible Loan to Kahr Medical (2005) Ltd.

Nov. 11, 2015
D-Pharm: Recruiting the First Patient for the THR-18 Clinical Trial

Nov. 1, 2015
D Pharm Ltd. – Termination of CEO and Other Changes

Nov. 1, 2015
D Pharm Ltd. – Termination of CEO and Other Changes

Oct. 27, 2015
D Pharm Ltd. - Update Regarding Focus of Company Activity and Infrastructure Adaptation

Oct. 26, 2015
Termination of the Non-Binding Letter on Intend

Oct. 25, 2015
Results of the General and Special Meeting dated October 25, 2015

Oct. 13, 2015
Final Results of KAHR Medical Ltd. Pre-clinical Trials

Oct. 12, 2015
Written Vote under the Companies Regulations

Sep. 29, 2015
Receipt of FDA Approval of the Accelerated Regulator Track for the OpRegen® to Treat Dry Age-Related Macular Degeneration

Sep. 10, 2015
D Pharm Ltd. - Approval of THR-18 Trial Protocol

Sep. 2, 2015
Approval of Patent Registration in Japan - ProtAb Ltd.

Aug. 25, 2015
the Extension of the Term of the Non-Binding Letter of Intend For a Private Placement Agreement

Aug. 17, 2015
Public Offering Results according to Supplementary Prospectus and Supplementary Notice

Aug. 16, 2015
Share Offering

Jul. 30, 2015
DPharm Ltd. – Receipt of Final Report for Clinical Trial Phase II

Jul. 30, 2015
Immediate Report – Kahr Medical (2005) Ltd.

Jul. 14, 2015
Receipt of US Patent of CellCure Neurosciences

Jul. 6, 2015
Written Vote under the Companies Regulations

Jun. 29, 2015
Submitting an Application To Ethical Committees for Approval of Stage I/IIa Clinical Trials of KAHR Medical Ltd.

Jun. 28, 2015
Signing of a Non-Binding Letter of Intend For a Private Placement Agreement

Jun. 7, 2015
Reverse Split

May. 31, 2015
Immediate Report

May. 26, 2015
Annual general and special meeting Results- May 26, 2015

May. 5, 2015
Allowance of Patent in Australia - ProtAb Ltd

May. 1, 2015
The Results of Protab Ltd.’s Pre-Clinical Trials

Apr. 22, 2015
Voting Deed According to the Company Regulations

Apr. 14, 2015
Allowance of Patent in Israel - ProtAb Ltd

Apr. 4, 2015
Investment in CellCure Neurosciences Ltd.

Apr. 4, 2015
Convertible loan to KAHR Medical (2005) Ltd.

Mar. 30, 2015
Immediate Report Concerning the Results of a Public Offering According to a Shelf Offer from March 30, 2015

Mar. 21, 2015
Amendment of Enlivex’s Reports

Mar. 4, 2015
Amendment to Convertible Loan Agreement in KAHR Medical (2005) Ltd.

Feb. 17, 2015
Cell Cure Neurosciences Initiates Phase I/IIa Trial and Granted Key US Patent for Retinal Pigment Epithelial (RPE) Stem Cells

Feb. 16, 2015
Expiration of the Option of Teva Under the License Agreement with CellCure Neurosciences

Feb. 15, 2015
Approval of 2015 Work Plan of D Pharm Ltd.

Feb. 15, 2015
A voting paper based on the Companies Regulations

Feb. 12, 2015
The Signing of an Agreement for a Convertible Loan with KAHR Medical (2005) Ltd

Jan. 31, 2015
Extension of Option Period regarding the License Agreement between Teva and CellCure Neurosciences

Jan. 26, 2015
Enlivex Granted EU Orphan Drug Designation for Lead Product ApoCell for Graft-versus-Host Disease

Jan. 22, 2015
report from D Pharm Company Ltd. – the results of a rights issue

Jan. 1, 2015
Extension of Option Period regarding the License Agreement between Teva and CellCure Neurosciences

Dec. 27, 2014
Publication of a Shelf Registration Report for an offer by way of rights of D-Pharm LTD

Dec. 17, 2014
Kahr Medical received government grant sum of 8.2 m shekels approved by the Chief Scientist office.

Dec. 12, 2014
ProtAb Ltd. Awarded Chinese Patent for Lead Humanized Antibody, Prozumab

Nov. 4, 2014
Initial results for clinical trial Phase IIa in THR-18 for D Pharm Ltd.

Nov. 3, 2014
Cell Cure Neurosciences Ltd. Receives FDA Authorization to Initiate Phase I/IIa Trial

Oct. 21, 2014
Written proxy pursuant to Companies Regulations (Voting in Writing and Position Statements) october 2014

Oct. 6, 2014
IND Submission to the FDA of Cell Cure Neuroscience Ltd.

Sep. 23, 2014
Notice of results from meeting and request by the company

Sep. 23, 2014
Hadasit Bio Invested $460,000 in Protab Company

Sep. 18, 2014
CellCure reports positive safety for the product

Sep. 11, 2014
Yigal Erlich- Chairman of the board of directors

Aug. 17, 2014
Notice from Warrant (Series 4) Holder

Aug. 17, 2014
RE: Immediate report concerning the general meeting of Company warrant (series 4) holders under Section 350 of the Companies Law

Aug. 13, 2014
Subjugation (lien) of the company's stocks held by the shareholder

Jul. 29, 2014
Decision in the Matter of the Extension of the Redemption Period and Reduction of the Price of Redemption of (Series 4) Options part 1

Jul. 29, 2014
Decision in the Matter of the Extension of the Redemption Period and Reduction of the Price of Redemption of (Series 4) Options part 2

May. 18, 2014
Enlivex- Completion Of Convertible Loan Recruitment

Feb. 18, 2014
Shareholders' Meeting to Approve New Directors

Dec. 24, 2013
Cell Cure, Enlivex and KAHR Medical to Receive NIS 12 Million (Over $3.4 Million USD) in Additional Government Grants

Dec. 16, 2013
Term Sheet Signed for Financing Enlivex

Nov. 28, 2013
Shareholders' Meeting to Approve New Directors, Payments to Directors, Outgoing CEO and New CEO

Sep. 9, 2013
KAHR Medical to Raise $2.5M at Pre-money Valuation of $13.5M

Aug. 12, 2013
Share Holder's Meeting to Approve Compensation Policy

May. 12, 2013
Cell Cure Neurosciences Ltd. Receives Significant Financing From the Israeli OCS and a BioTime Inc. Loan

Apr. 3, 2013
Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA

Feb. 4, 2013
KAHR expands and strengthens its intellectual property

Dec. 24, 2012
ProtAb and Enlivex receive CLAs

Nov. 26, 2012
Q3 Report Shows Capital Gain of 7 M NIS

Nov. 11, 2012
Cell Cure Neurosciences Ltd. Receives Additional Financing From BioTime Inc.

Oct. 24, 2012
Enlivex Therapeutics Announces Positive Results in Completion of Clinical Trial for the Treatment of Bone Marrow Transplant Recipients

Oct. 18, 2012
Einat Zisman, PhD, MBA appointed to the Hadasit Bio Holdings Board of Directors.

Oct. 16, 2012
Company’s ADR - HADSY - Now Blue Sky Exempt in Over 30 States

Oct. 16, 2012
Hadasit Bio-Holdings to Participate in Hadassah Centennial Convention

Sep. 12, 2012
Share holder's meeting to appoint new director

Sep. 4, 2012
Hadasit Bio raises 5.1 M NIS with over 99% exercise of rights

Aug. 13, 2012
Rights Issued to Current Share Holders and Warrant Holders

Jul. 30, 2012
Hadasit Bio Holdings Provides Convertible Loans to ProtAb Ltd. and Enlivex Ltd.

Jul. 21, 2012
Globes interviews CEO Ophir Shahaf

Jul. 19, 2012
Thrombotech Acquiered by D Pharm

Jul. 12, 2012
CEO Interviewed by Wall Street Reporter

Jun. 19, 2012
KAHR Medical raises 10.4 million NIS

Jun. 18, 2012
KAHR Medical raises over 10 million NIS

May. 30, 2012
CEO Ophir Shahaf comments on Thrombotech - D-Pharm mereger

May. 21, 2012
Thrombotech and D-Pharm Sign Purchase Agreement and Additional Investment

Apr. 17, 2012
Article on Hadasit Bio - Holdings by Leonard Zehr in BioTuesday

Apr. 8, 2012
The BIRD Foundation Grants BioMarCare and Ariadne $900k

Apr. 5, 2012
BioMarCare's $900k BIRD grant approved

Mar. 27, 2012
A Strategic Investment in BioMarCare Technologies Inc.

Mar. 27, 2012
BioMarCare Closes Strategic Investment by Micromedic, a Bio-Light Subsidiary

Mar. 13, 2012
HBL Share Holders Meeting and Extension of Options' Maturation Date

Mar. 7, 2012
Two portfolio companies receive OCS approvals

Feb. 28, 2012
Thrombotech Ltd. Receives IND Approval From the FDA

Feb. 28, 2012
Thrombotech Ltd. Approved for Phase IIa in the U.S.A.

Feb. 23, 2012
Thrombotech Ltd. Buyout Negotiations With D-Pharm Ltd

Jan. 19, 2012
Hadasit Bio-Holdings' Portfolio Company Thrombotech Raises $1.4M

Jan. 15, 2012
Enlivex has completed patient enrollment in its Phase I/II clinical trial

Jan. 10, 2012
Thrombotech Completes Additional Financing Round of $1.4 million

Jan. 10, 2012
Thrombotech Raises $1.4 M and Is Expanding Its Phase IIa Trial

Nov. 27, 2011
Recommendation to terminate Verto’s activity - not expected to affect company.

Nov. 14, 2011
4 portfolio companies have received government grants for over 10 M NIS in 2011

Oct. 30, 2011
BioMarCare receives approval for use of 400 samples from the Hadassah Medical Center

Jul. 27, 2011
About ADRs and how Hadasit Bio-Holdings can benefit from its ADR

Jul. 6, 2011
BioMarCare Ltd. receives initial approval for a grant from the BIRD Foundation

Jul. 3, 2011
HBL announces that Thrombotech has begun its Phase IIa clinical trial

Jun. 27, 2011
Hadasit Bio-Holdings Begins Trading in U.S. through Launch of ADR

Jun. 20, 2011
BNY Mellon Appointed as Depositary Bank by Hadasit Bio-Holdings, Ltd.

Jun. 20, 2011
An ADR program has been setup (OTCBB:HADSY) for trading in the US

Jun. 19, 2011
HBL announces an ADS trading program in the United States (OTCBB:HADSY)

May. 25, 2011
3 HBL Portfolio Companies Amongst 10 Promising Israeli Biotech Companies on the Verge of a Breakthrough (Calcalist)

Apr. 17, 2011
Sanofi aventis invests in KAHR Medical

Apr. 14, 2011
KAHR Medical to Raise $ 3 M for Development of Novel Cancer and Autoimmune Disease Drugs

Mar. 9, 2011
Poalim Sahar initiates coverage on HBL

Mar. 9, 2011
Hadasit Bio target is double its share price

Mar. 6, 2011
BioMarCare financing and clinical trial

Feb. 27, 2011
Article on HBL in Hadassah Magazine

Jan. 23, 2011
Article on HBL in Hadassah Magazine

Nov. 9, 2010
Attracting the life sciences to Jerusalem

Oct. 13, 2010
CellCure's 'breakthrough agreement with Big Pharma'

Oct. 10, 2010
HBL's subsidiary- CellCure makes the deal of the year

Oct. 10, 2010
The Cyclic Nature of Biotech Revolutions

Sep. 28, 2010
HBL and BioMarCare get positive PR from top IBI analyst in Globes

Sep. 13, 2010
"Investing in Israel for the greater good" Haaretz 13/09/2010

Aug. 24, 2010
Another Major Achievement for Hadasit Bio Holdings (Thrombotech completes phase I)